ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2023
Pharmacokinetics and Pharmacodynamics of Apixaban in Nephrotic Syndrome: Findings From a Phase 1a Trial.
Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Ten tips for the diagnosis and management of nephrotic syndrome.Clinical kidney journal · 2026Review
- Drug-Drug Interactions Between Oral Anticoagulants and Calcineurin Inhibitors in Nephrotic Syndrome for Management of Thromboembolism.Biomedicines · 2026Review
- Renal Vein Thrombosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026Review
- A multicenter prospective real-world cohort study of direct oral anticoagulant use for venous thromboembolism prophylaxis in nephrotic syndrome.BMC nephrology · 2026Observational
- Apixaban Concentrations and Effects on Coagulation in Patients With Nephrotic Syndrome.Kidney medicine · 2025Article
- Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists.Kidney international reports · 2025Article
- Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study.Kidney international reports · 2025Article
- Prophylactic and Therapeutic Anticoagulation in Nephrotic Syndrome Using Direct Acting Oral Anticoagulants.Kidney international reports · 2025Article
- Anticoagulation for the Prevention of Thrombotic Events in Nephrotic Syndrome.Kidney international reports · 2024Article
- Article
- Rivaroxaban for Thromboembolism Prophylaxis in Patients with Nephrotic Syndrome: A Single-Arm, Prospective Study.Kidney diseases (Basel, Switzerland) · 2024Article
- Prophylactic Anticoagulation in Nephrotic Syndrome.Kidney360 · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.